Table 3. Adverse events.

	Grade 1–2	Grade 3	Grade 4
Haematological toxic effects
Anaemia	12 (23%)	1 (2%)	0
Neutrophil count decreased	7 (13%)	3 (6%)	0
Platelet count decreased	11 (21%)	0	0
White blood cell decreased	9 (17%)	1 (2%)	0
Non-haematological toxic effects
Abdominal pain	6 (12%)	1 (2%)	0
Alanine aminotransferase increased	14 (27%)	3 (6%)	0
Alkaline phosphatase increased	4 (8%)	1 (2%)	0
Aspartate aminotransferase increased	20 (38%)	3 (6%)	0
Blood bilirubin increased	11 (21%)	0	0
Confusion	0	1 (2%)	0
Constipation	8 (15%)	0	0
Dehydration	0	1 (2%)	0
Diarrhoea	30 (58%)	3 (6%)	0
Fatigue	35 (67%)	4 (8%)	0
Headache	9 (17%)	0	0
Hyperglycaemia	6 (12%)	0	0
Hypertension	22 (42%)	6 (12%)	0
Hypertriglyceridaemia	0	1 (2%)	1 (2%)
Hypocalcaemia	7 (13%)	0	0
Hypomagnesaemia	9 (17%)	0	0
Hypophosphataemia	5 (10%)	0	0
INR increased	7 (13%)	0	0
Mucositis oral	9 (17%)	0	0
Nausea	32 (62%)	1 (2%)	0
Hand–foot syndrome	2 (4%)	1 (2%)	0
Pancreatitis	0	1 (2%)	0
Skin and subcutaneous tissue disorders (other)	6 (12%)	0	0
Skin hypopigmentation	7 (13%)	0	0
Thromboembolic event	0	0	1 (2%)
Urinary tract infection	0	1 (2%)	0
Vomiting	11 (21%)	0	0

Adverse events according to Common Terminology Criteria for Adverse Events 4.0, excluding grade 1–2 toxic effects that occurred in less than 10% of patients.